Age-Specific  ||| S:0 E:13 ||| JJ
Gastric  ||| S:13 E:21 ||| NNP
Cancer  ||| S:21 E:28 ||| NNP
Risk  ||| S:28 E:33 ||| NNP
Indicated  ||| S:33 E:43 ||| NNP
by  ||| S:43 E:46 ||| IN
the  ||| S:46 E:50 ||| DT
Combination  ||| S:50 E:62 ||| NNP
of  ||| S:62 E:65 ||| IN
Helicobacter  ||| S:65 E:78 ||| NNP
pylori  ||| S:78 E:85 ||| VBD
Sero-Status  ||| S:85 E:97 ||| JJ
and  ||| S:97 E:101 ||| CC
Serum  ||| S:101 E:107 ||| NNP
Pepsinogen  ||| S:107 E:118 ||| NNP
Levels  ||| S:118 E:125 ||| NNP
Serologic  ||| S:125 E:135 ||| NNP
screening  ||| S:135 E:145 ||| NN
of  ||| S:145 E:148 ||| IN
gastric  ||| S:148 E:156 ||| JJ
cancer  ||| S:156 E:163 ||| NN
( ||| S:163 E:164 ||| -LRB-
GC ||| S:164 E:166 ||| NNP
)  ||| S:166 E:168 ||| -RRB-
by  ||| S:168 E:171 ||| IN
serum  ||| S:171 E:177 ||| JJ
pepsinogens  ||| S:177 E:189 ||| NNS
( ||| S:189 E:190 ||| -LRB-
sPG ||| S:190 E:193 ||| NNP
)  ||| S:193 E:195 ||| -RRB-
levels  ||| S:195 E:202 ||| NNS
and  ||| S:202 E:206 ||| CC
Helicobacter  ||| S:206 E:219 ||| NNP
pylori  ||| S:219 E:226 ||| NNS
( ||| S:226 E:227 ||| -LRB-
Hp ||| S:227 E:229 ||| NNP
)  ||| S:229 E:231 ||| -RRB-
sero-status ||| S:231 E:242 ||| NNP
,  ||| S:242 E:244 ||| ,
though  ||| S:244 E:251 ||| RB
highly  ||| S:251 E:258 ||| RB
informative ||| S:258 E:269 ||| JJ
,  ||| S:269 E:271 ||| ,
has  ||| S:271 E:275 ||| VBZ
provided  ||| S:275 E:284 ||| VBN
heterogeneous  ||| S:284 E:298 ||| JJ
results ||| S:298 E:305 ||| NNS
.  ||| S:305 E:307 ||| .
Here ||| S:307 E:311 ||| RB
,  ||| S:311 E:313 ||| ,
we  ||| S:313 E:316 ||| PRP
have  ||| S:316 E:321 ||| VBP
evaluated  ||| S:321 E:331 ||| VBN
the  ||| S:331 E:335 ||| DT
modifying  ||| S:335 E:345 ||| JJ
effects  ||| S:345 E:353 ||| NNS
of  ||| S:353 E:356 ||| IN
demographic  ||| S:356 E:368 ||| JJ
factors  ||| S:368 E:376 ||| NNS
on  ||| S:376 E:379 ||| IN
the  ||| S:379 E:383 ||| DT
risk  ||| S:383 E:388 ||| NN
impact  ||| S:388 E:395 ||| NN
of  ||| S:395 E:398 ||| IN
Hp  ||| S:398 E:401 ||| NNP
sero-status ||| S:401 E:412 ||| NNP
/ ||| S:412 E:413 ||| NNP
sPG  ||| S:413 E:417 ||| JJ
levels  ||| S:417 E:424 ||| NNS
in  ||| S:424 E:427 ||| IN
gastric  ||| S:427 E:435 ||| JJ
cancer ||| S:435 E:441 ||| NN
,  ||| S:441 E:443 ||| ,
with  ||| S:443 E:448 ||| IN
particular  ||| S:448 E:459 ||| JJ
emphasis  ||| S:459 E:468 ||| NN
on  ||| S:468 E:471 ||| IN
age ||| S:471 E:474 ||| NN
.  ||| S:474 E:476 ||| .
A  ||| S:476 E:478 ||| DT
cross-sectional  ||| S:478 E:494 ||| JJ
study  ||| S:494 E:500 ||| NN
was  ||| S:500 E:504 ||| VBD
carried  ||| S:504 E:512 ||| VBN
out  ||| S:512 E:516 ||| RP
on  ||| S:516 E:519 ||| IN
1341  ||| S:519 E:524 ||| CD
individuals  ||| S:524 E:536 ||| NNS
( ||| S:536 E:537 ||| -LRB-
GC  ||| S:537 E:540 ||| NNP
=  ||| S:540 E:542 ||| SYM
578 ||| S:542 E:545 ||| CD
,  ||| S:545 E:547 ||| ,
healthy  ||| S:547 E:555 ||| JJ
=  ||| S:555 E:557 ||| CD
763 ||| S:557 E:560 ||| CD
) ||| S:560 E:561 ||| -RRB-
,  ||| S:561 E:563 ||| ,
who  ||| S:563 E:567 ||| WP
were  ||| S:567 E:572 ||| VBD
stratified  ||| S:572 E:583 ||| VBN
into  ||| S:583 E:588 ||| IN
two  ||| S:588 E:592 ||| CD
age  ||| S:592 E:596 ||| NN
groups ||| S:596 E:602 ||| NNS
:  ||| S:602 E:604 ||| :
35-59  ||| S:604 E:610 ||| CD
years  ||| S:610 E:616 ||| NNS
( ||| S:616 E:617 ||| -LRB-
middle-aged ||| S:617 E:628 ||| JJ
,  ||| S:628 E:630 ||| ,
n  ||| S:630 E:632 ||| VBG
=  ||| S:632 E:634 ||| SYM
830 ||| S:634 E:637 ||| CD
)  ||| S:637 E:639 ||| -RRB-
and  ||| S:639 E:643 ||| CC
â‰¥  ||| S:643 E:645 ||| CD
60  ||| S:645 E:648 ||| CD
years  ||| S:648 E:654 ||| NNS
( ||| S:654 E:655 ||| -LRB-
60  ||| S:655 E:658 ||| CD
years-plus ||| S:658 E:668 ||| NN
,  ||| S:668 E:670 ||| ,
n  ||| S:670 E:672 ||| VBG
=  ||| S:672 E:674 ||| SYM
511 ||| S:674 E:677 ||| CD
) ||| S:677 E:678 ||| -RRB-
.  ||| S:678 E:680 ||| .
Demographic  ||| S:680 E:692 ||| JJ
factors  ||| S:692 E:700 ||| NNS
and  ||| S:700 E:704 ||| CC
serological  ||| S:704 E:716 ||| JJ
states  ||| S:716 E:723 ||| NNS
( ||| S:723 E:724 ||| -LRB-
Hp  ||| S:724 E:727 ||| NNP
sero-staus  ||| S:727 E:738 ||| NNP
and  ||| S:738 E:742 ||| CC
sPG  ||| S:742 E:746 ||| JJ
levels ||| S:746 E:752 ||| NNS
)  ||| S:752 E:754 ||| -RRB-
were  ||| S:754 E:759 ||| VBD
recorded  ||| S:759 E:768 ||| VBN
by  ||| S:768 E:771 ||| IN
subject  ||| S:771 E:779 ||| JJ
interview  ||| S:779 E:789 ||| NN
and  ||| S:789 E:793 ||| CC
serum  ||| S:793 E:799 ||| JJ
ELISAs ||| S:799 E:805 ||| NN
,  ||| S:805 E:807 ||| ,
respectively ||| S:807 E:819 ||| RB
.  ||| S:819 E:821 ||| .
Covariate-specific  ||| S:821 E:840 ||| JJ
odds  ||| S:840 E:845 ||| NNS
ratios  ||| S:845 E:852 ||| NNS
were  ||| S:852 E:857 ||| VBD
calculated  ||| S:857 E:868 ||| VBN
by  ||| S:868 E:871 ||| IN
multivariable  ||| S:871 E:885 ||| JJ
logistic  ||| S:885 E:894 ||| JJ
regression ||| S:894 E:904 ||| NN
.  ||| S:904 E:906 ||| .
Hp  ||| S:906 E:909 ||| JJ
infection  ||| S:909 E:919 ||| NN
was  ||| S:919 E:923 ||| VBD
consistently  ||| S:923 E:936 ||| RB
associated  ||| S:936 E:947 ||| VBN
with  ||| S:947 E:952 ||| IN
increased  ||| S:952 E:962 ||| JJ
sPGI  ||| S:962 E:967 ||| JJ
and  ||| S:967 E:971 ||| CC
sPGII  ||| S:971 E:977 ||| JJ
levels  ||| S:977 E:984 ||| NNS
in  ||| S:984 E:987 ||| IN
the  ||| S:987 E:991 ||| DT
60  ||| S:991 E:994 ||| CD
year-plus ||| S:994 E:1003 ||| NN
,  ||| S:1003 E:1005 ||| ,
but  ||| S:1005 E:1009 ||| CC
not  ||| S:1009 E:1013 ||| RB
the  ||| S:1013 E:1017 ||| DT
middle-aged  ||| S:1017 E:1029 ||| JJ
group ||| S:1029 E:1034 ||| NN
.  ||| S:1034 E:1036 ||| .
The  ||| S:1036 E:1040 ||| DT
joint  ||| S:1040 E:1046 ||| JJ
examination  ||| S:1046 E:1058 ||| NN
of  ||| S:1058 E:1061 ||| IN
the  ||| S:1061 E:1065 ||| DT
variable  ||| S:1065 E:1074 ||| JJ
states  ||| S:1074 E:1081 ||| NNS
of  ||| S:1081 E:1084 ||| IN
the  ||| S:1084 E:1088 ||| DT
three  ||| S:1088 E:1094 ||| CD
serum  ||| S:1094 E:1100 ||| CD
biomarkers  ||| S:1100 E:1111 ||| NNS
( ||| S:1111 E:1112 ||| -LRB-
Hp  ||| S:1112 E:1115 ||| NNP
serology ||| S:1115 E:1123 ||| NN
,  ||| S:1123 E:1125 ||| ,
sPGI ||| S:1125 E:1129 ||| NNP
,  ||| S:1129 E:1131 ||| ,
and  ||| S:1131 E:1135 ||| CC
sPGI ||| S:1135 E:1139 ||| NNP
/ ||| S:1139 E:1140 ||| NNP
II  ||| S:1140 E:1143 ||| NNP
ratio ||| S:1143 E:1148 ||| NN
) ||| S:1148 E:1149 ||| -RRB-
,  ||| S:1149 E:1151 ||| ,
in  ||| S:1151 E:1154 ||| IN
the  ||| S:1154 E:1158 ||| DT
60  ||| S:1158 E:1161 ||| CD
year-plus  ||| S:1161 E:1171 ||| JJ
age  ||| S:1171 E:1175 ||| NN
group ||| S:1175 E:1180 ||| NN
,  ||| S:1180 E:1182 ||| ,
demonstrated  ||| S:1182 E:1195 ||| VBD
a  ||| S:1195 E:1197 ||| DT
stepwise  ||| S:1197 E:1206 ||| JJ
escalation  ||| S:1206 E:1217 ||| NN
of  ||| S:1217 E:1220 ||| IN
risk  ||| S:1220 E:1225 ||| NN
from  ||| S:1225 E:1230 ||| IN
the  ||| S:1230 E:1234 ||| DT
single  ||| S:1234 E:1241 ||| JJ
( ||| S:1241 E:1242 ||| -LRB-
sPGI  ||| S:1242 E:1247 ||| JJ
low ||| S:1247 E:1250 ||| JJ
;  ||| S:1250 E:1252 ||| :
OR  ||| S:1252 E:1255 ||| NNP
=  ||| S:1255 E:1257 ||| SYM
2.6 ||| S:1257 E:1260 ||| CD
) ||| S:1260 E:1261 ||| -RRB-
,  ||| S:1261 E:1263 ||| ,
to  ||| S:1263 E:1266 ||| TO
double  ||| S:1266 E:1273 ||| VB
( ||| S:1273 E:1274 ||| -LRB-
sPGI  ||| S:1274 E:1279 ||| JJ
low ||| S:1279 E:1282 ||| JJ
/ ||| S:1282 E:1283 ||| NNP
sPGI ||| S:1283 E:1287 ||| NNP
/ ||| S:1287 E:1288 ||| NNP
II  ||| S:1288 E:1291 ||| NNP
low ||| S:1291 E:1294 ||| JJ
;  ||| S:1294 E:1296 ||| :
OR  ||| S:1296 E:1299 ||| NNP
=  ||| S:1299 E:1301 ||| SYM
3.55 ||| S:1301 E:1305 ||| CD
,  ||| S:1305 E:1307 ||| ,
and  ||| S:1307 E:1311 ||| CC
Hp  ||| S:1311 E:1314 ||| NNP
positive ||| S:1314 E:1322 ||| JJ
/ ||| S:1322 E:1323 ||| CD
sPGI  ||| S:1323 E:1328 ||| JJ
low ||| S:1328 E:1331 ||| JJ
;  ||| S:1331 E:1333 ||| :
OR  ||| S:1333 E:1336 ||| NNP
=  ||| S:1336 E:1338 ||| SYM
5.0 ||| S:1338 E:1341 ||| CD
)  ||| S:1341 E:1343 ||| -RRB-
and  ||| S:1343 E:1347 ||| CC
ultimately  ||| S:1347 E:1358 ||| RB
triple  ||| S:1358 E:1365 ||| JJ
( ||| S:1365 E:1366 ||| -LRB-
Hp  ||| S:1366 E:1369 ||| FW
positive ||| S:1369 E:1377 ||| FW
/ ||| S:1377 E:1378 ||| FW
PGI  ||| S:1378 E:1382 ||| FW
low ||| S:1382 E:1385 ||| FW
/ ||| S:1385 E:1386 ||| FW
PGI ||| S:1386 E:1389 ||| FW
/ ||| S:1389 E:1390 ||| FW
II  ||| S:1390 E:1393 ||| NNP
low ||| S:1393 E:1396 ||| JJ
;  ||| S:1396 E:1398 ||| :
OR  ||| S:1398 E:1401 ||| NNP
=  ||| S:1401 E:1403 ||| SYM
10.48 ||| S:1403 E:1408 ||| CD
)  ||| S:1408 E:1410 ||| -RRB-
positive  ||| S:1410 E:1419 ||| JJ
states ||| S:1419 E:1425 ||| NNS
,  ||| S:1425 E:1427 ||| ,
in  ||| S:1427 E:1430 ||| IN
reference  ||| S:1430 E:1440 ||| NN
to  ||| S:1440 E:1443 ||| TO
the  ||| S:1443 E:1447 ||| DT
triple  ||| S:1447 E:1454 ||| JJ
negatives ||| S:1454 E:1463 ||| NNS
.  ||| S:1463 E:1465 ||| .
However ||| S:1465 E:1472 ||| RB
,  ||| S:1472 E:1474 ||| ,
this  ||| S:1474 E:1479 ||| DT
pattern  ||| S:1479 E:1487 ||| NN
was  ||| S:1487 E:1491 ||| VBD
not  ||| S:1491 E:1495 ||| RB
exhibited  ||| S:1495 E:1505 ||| VBN
in  ||| S:1505 E:1508 ||| IN
the  ||| S:1508 E:1512 ||| DT
middle-aged  ||| S:1512 E:1524 ||| JJ
subjects ||| S:1524 E:1532 ||| NNS
.  ||| S:1532 E:1534 ||| .
Age  ||| S:1534 E:1538 ||| NN
was  ||| S:1538 E:1542 ||| VBD
clearly  ||| S:1542 E:1550 ||| RB
identified  ||| S:1550 E:1561 ||| VBN
as  ||| S:1561 E:1564 ||| IN
a  ||| S:1564 E:1566 ||| DT
modifying  ||| S:1566 E:1576 ||| JJ
factor  ||| S:1576 E:1583 ||| NN
on  ||| S:1583 E:1586 ||| IN
the  ||| S:1586 E:1590 ||| DT
risk  ||| S:1590 E:1595 ||| NN
projection  ||| S:1595 E:1606 ||| NN
of  ||| S:1606 E:1609 ||| IN
the  ||| S:1609 E:1613 ||| DT
combined  ||| S:1613 E:1622 ||| JJ
states  ||| S:1622 E:1629 ||| NNS
of  ||| S:1629 E:1632 ||| IN
Hp  ||| S:1632 E:1635 ||| NNP
serology  ||| S:1635 E:1644 ||| NN
and  ||| S:1644 E:1648 ||| CC
sPG  ||| S:1648 E:1652 ||| JJ
levels  ||| S:1652 E:1659 ||| NNS
in  ||| S:1659 E:1662 ||| IN
gastric  ||| S:1662 E:1670 ||| JJ
cancer  ||| S:1670 E:1677 ||| NN
screening ||| S:1677 E:1686 ||| NN
,  ||| S:1686 E:1688 ||| ,
reflected  ||| S:1688 E:1698 ||| VBD
by  ||| S:1698 E:1701 ||| IN
the  ||| S:1701 E:1705 ||| DT
augmented  ||| S:1705 E:1715 ||| NN
( ||| S:1715 E:1716 ||| -LRB-
~10.5  ||| S:1716 E:1722 ||| FW
fold ||| S:1722 E:1726 ||| FW
)  ||| S:1726 E:1728 ||| -RRB-
risk  ||| S:1728 E:1733 ||| NN
of  ||| S:1733 E:1736 ||| IN
GC  ||| S:1736 E:1739 ||| NNP
in  ||| S:1739 E:1742 ||| IN
the  ||| S:1742 E:1746 ||| DT
triple  ||| S:1746 E:1753 ||| JJ
positive  ||| S:1753 E:1762 ||| JJ
( ||| S:1762 E:1763 ||| -LRB-
Hp  ||| S:1763 E:1766 ||| FW
positive ||| S:1766 E:1774 ||| FW
/ ||| S:1774 E:1775 ||| FW
sPGI  ||| S:1775 E:1780 ||| FW
low ||| S:1780 E:1783 ||| FW
/ ||| S:1783 E:1784 ||| FW
sPGI ||| S:1784 E:1788 ||| FW
/ ||| S:1788 E:1789 ||| FW
II  ||| S:1789 E:1792 ||| NNP
low ||| S:1792 E:1795 ||| JJ
)  ||| S:1795 E:1797 ||| -RRB-
60  ||| S:1797 E:1800 ||| CD
year-plus  ||| S:1800 E:1810 ||| JJ
subjects ||| S:1810 E:1818 ||| NNS
,  ||| S:1818 E:1820 ||| ,
which  ||| S:1820 E:1826 ||| WDT
was  ||| S:1826 E:1830 ||| VBD
not  ||| S:1830 E:1834 ||| RB
evident  ||| S:1834 E:1842 ||| JJ
in  ||| S:1842 E:1845 ||| IN
the  ||| S:1845 E:1849 ||| DT
middle-aged  ||| S:1849 E:1861 ||| JJ
group ||| S:1861 E:1866 ||| NN
.  ||| S:1866 E:1868 ||| .
